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Background: The use of synthetic DMARDS (sDMARDs) in spondy-
loarthritis (SpA) has been increasingly questioned and restricted
to peripheral disease, on the other hand, the use of immunobio-
logical agents for the treatment of SpA has been further
improved by the release of new drugs with other mechanisms
than anti-TNF, such as secukinumab (anti-IL17, SEC) and ustekinu-
mab (anti-IL12/23, UST). The objective of our study is to describe
clinical and treatment data of a SpA patients cohort followed at
the outpatient clinic of a Brazilian single center.
Methods: 516 SpA patients evaluated from January 2017 to Janu-
ary 2018. Data from electronic medical records assessed including
diagnosis, disease characteristics, treatment and disease activity
at the last visit.
Results: Among all patients 195 (37.8%) were classified as Ankylosing
Spondylitis (AS), 198 (38.3%) psoriasis arthritis (PsA), 66 (12.8%) axial
non-radiographic or peripheral SpA, 42 (8.1%) SpA related to inflam-
matory bowel disease and 15 (3.0%) as reactive arthritis patients.
From all SpA patients 190 (36.8%) have no axial disease, with isolated
peripheral arthritis. Regarding treatment, 321 (62.2%) patients used
sDMARDs as monotherapy or in association [156/321 (48.6%) metho-
trexate (MTX); 125/321 (38.9%) sulfasalazine (SSZ); 53/321 (10.3%)
leflunomide (LFN) and 30/321 (9.3%) other sDMARDs] 298 (57.7%)
patients used NSAIDs. Concerning biological therapy 204 (39,5%) re-
ceived biological DMARDs (bDMARDs) [68 infliximab (IFX), 59 adali-
mumab (ADA), 35 etanercept (ETA), 6 golimumab (GOL), 2
certolizumab pegol (CTZ), 23 secukinumab (SEC), 10 ustekinumab
(UST), 1 rituximab (RTX)]. AS patients 43/52 (82.7%) are HLA-B27 posi-
tive; 152/195 (77.9%) received NSAIDs; 95/195 (48.7%) used sDMARDs
(23.1% MTX and 72.6% SSZ) and 79/195 (40.5%) used bDMARDs (31
INF, 22 ADA, 19 ETA, 3 GOL, 3 SEC, 1 UST). Among the 198 PsA pa-
tients 148/198 (74.7%) have solely peripheral involvement; 146/198
(73.7%) were under sDMARDs (78.8% MTX and 26.7% LNF) and 77/
198 38.9% were receiving bDMARDs (24 IFX, 18 ADA, 10 ETA, 19 SEC,
6 UST, 1 RTX). Concerning disease activity, 25/125 (20%) of AS pa-
tients had ASDAS ≥ 2.1 and 42/198 (21%) of PsA patients had active
arthritis in the last visit.
Conclusions: The description of epidemiological and clinical data of
this cohort reinforces high prevalence of peripheral disease in Brazil-
ian SpA patients. This fact could explain the wide use of sDMARDs in
these patients. The frequency use of bDMARDs is in parallel with lit-
erature data including non-antiTNF drugs as SEC and UST.
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Background: Isotretinoin is a synthetic vitamin A derivative regarded
as the most effective agent in the treatment of acne. Despite this,
the rheumatic side-effects of this drug are still unknown for many
rheumatologists. Our aim is to report a case of isotretinoin mimetiz-
ing a rheumatologic disease and its evolution.
Case report: A 16 year old male patient presented at the rheumato-
logic clinic complaining of severe progressive back pain of sudden
onset with inability to walk. Over the last 2 weeks, he had already re-
ceived 2 doses of intramuscular corticoid with no relief. He was previ-
ously healthy, except for moderate acne, which he was treating with
isotretinoin. The back pain started 20 days after the beginning of iso-
tretinoin and the drug was discontinued after 6 weeks due persistent
pain. At his first rheumatologic visit, he was already 30 days without
the medication. Examination revealed limitation of back movement
in all planes and no peripheral arthritis or enthesitis. The patient had
no other findings for SAPHO (synovitis, acne, pustulosis, hyperostosis,
and osteitis syndrome) and had no history or signs of active infection
or tuberculosis. Magnetic resonance imaging (MRI) showed evidence
of bilateral sacroiliitis and osteitis pubis. Full therapeutic dose of non-
steroidal anti-inflammatory drug (NSAID) was prescribed. On the in-
vestigation, HLA-B27 antigen was absent, viral serologies were nega-
tive, erythrocyte sedimentation rate (ESR) was 68mm and C-reactive
protein was 0.7mg/dL. After 2 weeks of NSAID, the pain reduced, and
patient ability to walk was completely restored after one month of
continuous NSAID. Laboratory control showed normalization of in-
flammatory markers and the patient no longer had to take NSAIDs.
Conclusion: In our case, acute sacroiliitis could be an adverse effect
of isotretinoin that improved with its discontinuation and with
NSAID. In another case report, patient had to use biological therapy
for a short period of time, remaining asymptomatic after drug cessa-
tion. Therefore, the rheumatologist should be aware of the possibility
of sacroiliitis caused by isotretinoin before establishing a definitive
diagnosis of chronic rheumatologic disease.
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Since December 2016, Brazil is experiencing an upsurge of yellow
fever virus activity. In January 2018, an informative Disease Outbreak
News from the World Health Organization (WHO), states the need for
control the yellow fever through the Vaccination, since this is the sin-
gle most important measure for preventing this endemic disease
with high mortality rates (40-50%).
However, one of the main contraindications for this YFV is
immunosuppression, a common condition among rheumatic pa-
tients, what raising many questions and hesitations regarding the
safety on application of the YFV for this special group. Both, pa-
tients and health professionals had been faced with the dilemma,
vaccinated or not?
To Understand the real scenario of adherence to the YFV during the
mass vaccination campaign, according to the rheumatic patient's
perspective.
A qualitative research, conducted through an electronic survey, be-
tween February 25 and April 17, 2018, published by social networks
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